@bens1
This test was announced in 2024 I believe. It combines PSA with tests for some "epigenetic" gene changes to get better accuracy.. This test is available from a single private lab, and perhaps with limited availability.

I know little about this test, which is a thoughtful and promising idea, nor the detail of their clinical data, particularly their PSA data. Without digging deeper, their comparative claims of PSA clinical performance raises questions for me.

First, was the PSA data taken from the medical literature? Was it based on simply the finding of an elevated PSA followed by a biopsy? PSA should only be used by an established rising value over time. A single value by itself would be improper clinical use of PSA. I don't think I've looked at recent sensitivity and specificity data for PSA using specific PSA "velocity" or trending criteria. I'm sure it exists, and I would expect it to be better than the data the company reports for PSA.

Second: How was the biopsy done in the PSA data group? Was it done with the accuracy of targeted MRI/US Fusion biopsies? Dramatic impact on sensitivity and specificity calculations versus earlier 12 Core TRUS biopsies, or systematic biopsies.

I'm not going to dig into the study designs and the data quality. These are the questions I immediately think of if I were to look.